MustGrow Biologics at 20th iif: sales grow as Bayer backs pipeline

MustGrow reported TerraSante sales of CAD 875,000 as of August 15, 2026, up 46% from 2025, with all incoming product pre-sold; production is about 800 bags per month versus nameplate capacity of 2,000. Management targets doubling 2025 sales by year-end 2026, but manufacturing constraints and regulatory timelines remain key limits; the company reported negative EBITDA of $3 million and remains unprofitable. Bayer is investing US$35 million to US$40 million in TerraMG registration across Europe, Africa and the Middle East, and MustGrow received its first milestone payment in June 2026.

Analysis

The investable issue is execution conversion, not market size: MGRO’s reported sell-through does not yet prove repeatable, profitable scale. Current output is well below stated nameplate capacity, and the asset-light model shifts the bottleneck to third-party process control, logistics and the volume forecasts needed to induce manufacturer investment. If those improve, additional supply could convert existing grower interest into revenue without equivalent company-funded capex; if not, pre-sold product simply caps growth. Verify reported sales basis, product mix, realized gross margin and cash burn before underwriting the stated capacity economics.

Bayer’s registration funding is meaningful external validation, but it is not evidence of near-term TerraMG sales: regulatory timelines remain the gating item, and the next milestone is uncertain. In the near term, presentation-driven interest can move this small-cap more quickly than fundamentals. Over 1–3 months, reported production and sales are the test; over 6–18 months, registrations and manufacturer capacity determine whether TerraSante’s traction becomes a scalable business and TerraMG adds value. Nutrien could benefit from incremental distribution volume, while growers gain another potential input option; neither effect is yet quantifiable. Bayer’s partnership also makes it premature to frame the technology as a broad threat to incumbent crop-protection businesses.

Contrarian point: “sold out” can signal constrained supply as much as product-market fit. The reported market opportunity and management’s margin/capacity estimates are not independently verified, and a large fully diluted share count alongside ongoing losses makes dilution and execution risk material. Treat MGRO as high-variance optionality, not a proven growth compounder.

Key Decisions for Investors

• MGRO: keep on a catalyst watchlist rather than chase presentation-related strength. Consider only a small, staged position after quarterly disclosures confirm rising output and sales conversion; upside depends on capacity unlocking, while downside includes production delays, cash burn and dilution. No entry price is supportable from the supplied data.
• Use the next company filing to test the thesis: verify sales on a comparable reporting basis, realized gross margin, cash usage and progress from current production toward stated nameplate capacity. Failure to improve output or sales would weaken the demand-to-growth case.
• Track TerraMG separately from TerraSante. Treat Bayer’s spending as validation and support for registration work, not booked commercial demand; reassess on a disclosed regulatory milestone or a confirmed change to the approval timetable.
• Do not pair against NTR or Bayer on this evidence alone: any distribution benefit or competitive substitution is too early and too small to establish a measurable earnings impact. Falsifiers include deteriorating MGRO sales conversion, persistent manufacturing slippage, or material regulatory delays.